Biodyne Co. Ltd.
Biodyne Co., Ltd. engages in the development, manufacture, and sale of liquid-based cytology (LBC) equipment and reagent kits for cancer diagnosis in South Korea. The company offers PATHPLORER solution, which preserves and fixes the collected cells; PATHPLORER LBC system, an equipment for processing liquid cytology samples for cancer diagnosis. It exports its products to Japan, Russia, Portugal, … Read more
Biodyne Co. Ltd. (314930) - Total Assets
Latest total assets as of September 2025: ₩43.45 Billion KRW
Based on the latest financial reports, Biodyne Co. Ltd. (314930) holds total assets worth ₩43.45 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Biodyne Co. Ltd. - Total Assets Trend (2018–2024)
This chart illustrates how Biodyne Co. Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Biodyne Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Biodyne Co. Ltd.'s total assets of ₩43.45 Billion consist of 50.4% current assets and 49.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩4.82 Billion | 10.9% |
| Accounts Receivable | ₩716.61 Million | 1.6% |
| Inventory | ₩436.78 Million | 1.0% |
| Property, Plant & Equipment | ₩10.84 Billion | 24.4% |
| Intangible Assets | ₩3.35 Billion | 7.5% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Biodyne Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biodyne Co. Ltd.'s current assets represent 50.4% of total assets in 2024, an increase from 35.0% in 2018.
- Cash Position: Cash and equivalents constituted 10.9% of total assets in 2024, up from 0.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, a decrease from 58.0% in 2018.
- Asset Diversification: The largest asset category is property, plant & equipment at 24.4% of total assets.
Biodyne Co. Ltd. Competitors by Total Assets
Key competitors of Biodyne Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Beijing Centergate Technologies Holding Co Ltd
SHE:000931
|
China | CN¥3.82 Billion |
|
Blue Sail Medical Co Ltd
SHE:002382
|
China | CN¥16.46 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥28.98 Billion |
|
Allmed Medical Products Co Ltd Class A
SHE:002950
|
China | CN¥5.35 Billion |
|
Inix Technologies Holdings Bhd
KLSE:0094
|
Malaysia | RM72.53 Million |
|
Focus Point Holdings Bhd
KLSE:0157
|
Malaysia | RM328.19 Million |
|
Careplus Group Bhd
KLSE:0163
|
Malaysia | RM286.61 Million |
|
LKL International Bhd
KLSE:0182
|
Malaysia | RM173.46 Million |
Biodyne Co. Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Biodyne Co. Ltd. generates 0.12x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Biodyne Co. Ltd. generates $ 0.02 in net profit.
Biodyne Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 27.99 | 16.89 | 1.20 |
| Quick Ratio | 26.98 | 16.57 | 1.01 |
| Cash Ratio | 0.00 | 8.04 | 0.00 |
| Working Capital | ₩20.90 Billion | ₩ 20.49 Billion | ₩ 1.11 Billion |
Biodyne Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between Biodyne Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.87 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 0.8% |
| Total Assets | ₩44.35 Billion |
| Market Capitalization | $144.24 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biodyne Co. Ltd.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Biodyne Co. Ltd.'s assets grew by 0.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Biodyne Co. Ltd. (2018–2024)
The table below shows the annual total assets of Biodyne Co. Ltd. from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩44.35 Billion | +0.82% |
| 2023-12-31 | ₩43.99 Billion | -3.14% |
| 2022-12-31 | ₩45.41 Billion | -0.89% |
| 2021-12-31 | ₩45.82 Billion | +81.52% |
| 2020-12-31 | ₩25.24 Billion | +8.57% |
| 2019-12-31 | ₩23.25 Billion | +80.03% |
| 2018-12-31 | ₩12.92 Billion | -- |